ARHGAP17

Across TCGA pan-cancer cohorts, ARHGAP17 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGAP17 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGAP17 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARHGAP17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where ARHGAP17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	1.000	0.621	.005	16	view →
LUAD	DFS	Median	All	0.771	0.488	.002	13	view →
GBM	OS	Tertile	All	0.246	0.579	.001	12	view →
PDAC	OS	Median	All	0.916	0.816	.014	9	view →
LSCC	OS	Median	All	0.921	1.000	.010	8	view →
UCEC	DFS	Median	All	0.936	1.000	.021	4	view →
HNSC	OS	Tertile	III,IV	0.569	0.812	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARHGAP17–CCRCC (OS)

Open the CCRCC breakdown →